CN112654353A - 用于治疗眼部疾病的方法和药物成分 - Google Patents

用于治疗眼部疾病的方法和药物成分 Download PDF

Info

Publication number
CN112654353A
CN112654353A CN201980054524.XA CN201980054524A CN112654353A CN 112654353 A CN112654353 A CN 112654353A CN 201980054524 A CN201980054524 A CN 201980054524A CN 112654353 A CN112654353 A CN 112654353A
Authority
CN
China
Prior art keywords
compound
subject
camkk2
ocular
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054524.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯科特·W·卡曾思
普里亚瑟姆·S·梅图
大卫·M·古登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN112654353A publication Critical patent/CN112654353A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980054524.XA 2018-08-20 2019-08-20 用于治疗眼部疾病的方法和药物成分 Pending CN112654353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
US62/719,938 2018-08-20
PCT/US2019/047309 WO2020041344A1 (en) 2018-08-20 2019-08-20 Methods and compositions for drugs to treat ophthalmic diseases

Publications (1)

Publication Number Publication Date
CN112654353A true CN112654353A (zh) 2021-04-13

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054524.XA Pending CN112654353A (zh) 2018-08-20 2019-08-20 用于治疗眼部疾病的方法和药物成分

Country Status (14)

Country Link
US (2) US12221447B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534202A (cg-RX-API-DMAC7.html)
KR (1) KR20210049857A (cg-RX-API-DMAC7.html)
CN (1) CN112654353A (cg-RX-API-DMAC7.html)
AU (1) AU2019326448A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109809A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003607A2 (cg-RX-API-DMAC7.html)
IL (1) IL280952A (cg-RX-API-DMAC7.html)
MX (1) MX2021002028A (cg-RX-API-DMAC7.html)
SG (1) SG11202101522WA (cg-RX-API-DMAC7.html)
TW (1) TW202021968A (cg-RX-API-DMAC7.html)
WO (1) WO2020041344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なCaMKK阻害剤
US9733406B2 (en) * 2006-01-13 2017-08-15 Crysoptix Kk Organic compound, anisotropic optical film and method of production thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600763D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
EP2638126B1 (en) * 2010-11-09 2015-02-18 Crysoptix K.K. Negative dispersion retardation plate and achromatic circular polarizer
SG194625A1 (en) 2011-05-23 2013-12-30 Sanofi Sa Process for the preparation of deuterated compounds containing n-alkyl groups
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なCaMKK阻害剤
US9733406B2 (en) * 2006-01-13 2017-08-15 Crysoptix Kk Organic compound, anisotropic optical film and method of production thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROSHI TOKUMITSU: "STO-609, a Specific Inhibitor of the Ca2 /Calmodulin-dependent Protein Kinase Kinase" *

Also Published As

Publication number Publication date
IL280952A (en) 2021-04-29
WO2020041344A1 (en) 2020-02-27
EP3840745A4 (en) 2022-06-08
WO2020041344A4 (en) 2020-03-26
AU2019326448A1 (en) 2021-03-11
CO2021003607A2 (es) 2021-07-30
MX2021002028A (es) 2021-07-21
BR112021003189A2 (pt) 2021-05-11
US20210198266A1 (en) 2021-07-01
KR20210049857A (ko) 2021-05-06
TW202021968A (zh) 2020-06-16
SG11202101522WA (en) 2021-03-30
US12221447B2 (en) 2025-02-11
US20250122209A1 (en) 2025-04-17
EP3840745A1 (en) 2021-06-30
JP2021534202A (ja) 2021-12-09
CA3109809A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
JP7332186B2 (ja) アルデヒドコンジュゲートおよびその使用
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
RU2268732C2 (ru) Способы лечения митохондриальных нарушений
KR101740076B1 (ko) Jak 경로의 억제를 위한 조성물 및 방법
TW200916472A (en) Sirtuin modulating compounds
TW200918542A (en) Sirtuin modulating compounds
US20160289271A1 (en) Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings
Wang et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation
JP2014530870A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
JP2019523260A (ja) キラルペプチド
Pan et al. Baicalein—A potent pro-homeostatic regulator of microglia in retinal ischemic injury
JP2024133636A (ja) 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
WO2025019473A1 (en) Isoxazole-3-carboxyamide compounds for enhancing telomerase reverse transcriptase (tert) expression
US20230263767A1 (en) Composition for preventing, alleviating, or treating inflammatory disease containing isookanin or salt thereof as active ingredient
US11701374B1 (en) 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression
US12233063B2 (en) Compositions and methods for treating eye disorders
US20230285556A1 (en) Methods and compositions for treating cancer
EP3525819A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
JP7848227B2 (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
WO2024029597A1 (ja) IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するドライアイ治療薬
CN114886909A (zh) 包含腺苷衍生物的用于预防或治疗视网膜疾病或视神经疾病的药物组合物
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
US7074938B2 (en) Method for the synthesis of soritin compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413

WD01 Invention patent application deemed withdrawn after publication